Literature DB >> 28017864

Modifying effects of carboxyl group on the interaction of recombinant S100A8/A9 complex with tyrosinase.

Fatemeh NematiNiko1, Koorosh Goodarzvand Chegini2, Hamideh Asghari3, Abbas Amini4, Nematollah Gheibi5.   

Abstract

Tyrosinase is a determinant enzyme for modulating melanin production as its abnormal activity can result in an increased amount of melanin. Reduction of tyrosinase activity has been targeted for preventing and healing hyperpigmentation of skin, such as melanoma and age related spots. The aim of this systematic study is to investigate whether recombinant S100A8/A9 and its modified form reduce the activity of mushroom tyrosinase (MT) through changing its structure. Recombinant His-Tagged S100A8 and S100A9 are expressed in Escherichia coli BL21 (DE3) and modified using Woodward's reagent K which is a carboxyl group modifier. The structures of S100A8/A9 and its modified form are studied using fluorescence and circular dichroism spectroscopy, and the activity of MT is measured using UV-visible spectrophotometry in the presence of its substrate, L-3,4-dihydroxyphenylalanine (L-DOPA). The results show a lower stability of the modified protein when compared with its unmodified form. The interaction of S100A8/A9 with MT changes the structure and successfully reduces the activity of mushroom tyrosinase. Recombinant S100A8/A9 complex decreases MT activity which can control malignant melanoma, the most dangerous type of skin cancer.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Enzyme activity; Mushroom tyrosinase; Protein modification; S100A8/A9; Skin cancer

Mesh:

Substances:

Year:  2016        PMID: 28017864     DOI: 10.1016/j.bbapap.2016.12.013

Source DB:  PubMed          Journal:  Biochim Biophys Acta Proteins Proteom        ISSN: 1570-9639            Impact factor:   3.036


  1 in total

Review 1.  Calprotectin (S100A8/S100A9): a key protein between inflammation and cancer.

Authors:  Fatemeh Shabani; Alireza Farasat; Majid Mahdavi; Nematollah Gheibi
Journal:  Inflamm Res       Date:  2018-08-06       Impact factor: 4.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.